Lantern Pharma (LTRN) Competitors $3.31 +0.19 (+6.09%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LTRN vs. PRPH, BTAI, TNXP, LPTX, MCRB, VXRT, ADAG, DERM, TELO, and RANIShould you be buying Lantern Pharma stock or one of its competitors? The main competitors of Lantern Pharma include ProPhase Labs (PRPH), BioXcel Therapeutics (BTAI), Tonix Pharmaceuticals (TNXP), Leap Therapeutics (LPTX), Seres Therapeutics (MCRB), Vaxart (VXRT), Adagene (ADAG), Journey Medical (DERM), Telomir Pharmaceuticals (TELO), and Rani Therapeutics (RANI). These companies are all part of the "pharmaceutical products" industry. Lantern Pharma vs. ProPhase Labs BioXcel Therapeutics Tonix Pharmaceuticals Leap Therapeutics Seres Therapeutics Vaxart Adagene Journey Medical Telomir Pharmaceuticals Rani Therapeutics Lantern Pharma (NASDAQ:LTRN) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, community ranking, risk, profitability, analyst recommendations, dividends, media sentiment and valuation. Does the media favor LTRN or PRPH? In the previous week, Lantern Pharma and Lantern Pharma both had 1 articles in the media. ProPhase Labs' average media sentiment score of -0.07 beat Lantern Pharma's score of -0.79 indicating that ProPhase Labs is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative ProPhase Labs 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Does the MarketBeat Community prefer LTRN or PRPH? ProPhase Labs received 102 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 75.00% of users gave Lantern Pharma an outperform vote while only 50.00% of users gave ProPhase Labs an outperform vote. CompanyUnderperformOutperformLantern PharmaOutperform Votes1275.00% Underperform Votes425.00% ProPhase LabsOutperform Votes11450.00% Underperform Votes11450.00% Which has more risk & volatility, LTRN or PRPH? Lantern Pharma has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.1, indicating that its share price is 110% less volatile than the S&P 500. Which has better valuation and earnings, LTRN or PRPH? Lantern Pharma has higher earnings, but lower revenue than ProPhase Labs. Lantern Pharma is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantern PharmaN/AN/A-$15.96M-$1.65-2.01ProPhase Labs$44.38M0.92-$16.78M-$1.21-1.77 Do institutionals & insiders have more ownership in LTRN or PRPH? 28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are owned by institutional investors. 7.3% of Lantern Pharma shares are owned by insiders. Comparatively, 20.7% of ProPhase Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is LTRN or PRPH more profitable? Lantern Pharma has a net margin of 0.00% compared to ProPhase Labs' net margin of -146.39%. Lantern Pharma's return on equity of -46.40% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets Lantern PharmaN/A -46.40% -42.58% ProPhase Labs -146.39%-54.04%-28.65% Do analysts recommend LTRN or PRPH? ProPhase Labs has a consensus price target of $11.00, suggesting a potential upside of 414.02%. Given ProPhase Labs' stronger consensus rating and higher possible upside, analysts plainly believe ProPhase Labs is more favorable than Lantern Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryProPhase Labs beats Lantern Pharma on 10 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Lantern Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LTRN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LTRN vs. The Competition Export to ExcelMetricLantern PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.65M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-2.019.93115.5615.18Price / SalesN/A381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book0.885.324.665.02Net Income-$15.96M$153.56M$119.06M$225.46M7 Day Performance-0.90%0.11%0.80%0.37%1 Month Performance-10.78%15.22%5.65%3.57%1 Year Performance20.80%41.14%36.76%29.44% Lantern Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LTRNLantern Pharma0.9061 of 5 stars$3.31+6.1%N/A+25.5%$35.65MN/A-2.0120News CoveragePositive NewsGap DownPRPHProPhase Labs3.0977 of 5 stars$2.14-6.6%$11.00+414.0%-51.9%$43.69M$44.38M-1.77130News CoverageBTAIBioXcel Therapeutics4.1811 of 5 stars$0.64-3.0%$5.00+677.5%-85.4%$26.20M$2.40M-0.1890Short Interest ↑News CoverageTNXPTonix Pharmaceuticals3.6345 of 5 stars$0.14-6.7%$53.50+38,306.3%-99.1%$19.12M$7.77M0.00103News CoverageLPTXLeap Therapeutics3.1154 of 5 stars$3.74flat$10.40+178.1%+144.8%$95.74M$1.50M-1.8740Positive NewsGap UpMCRBSeres Therapeutics3.8449 of 5 stars$0.82flat$5.08+518.5%-42.9%$139.89M$126.32M-0.70233Upcoming EarningsGap DownVXRTVaxart1.9014 of 5 stars$0.77flat$3.00+289.7%+19.2%$136.60M$15.65M-1.67109Upcoming EarningsNews CoverageADAGAdagene3.2775 of 5 stars$3.00+5.3%$5.00+66.7%+127.6%$132.81M$18.11M0.00260DERMJourney Medical3.4208 of 5 stars$6.17+7.3%$9.38+51.9%N/A$127.89M$77.68M-308.5090Upcoming EarningsShort Interest ↓High Trading VolumeTELOTelomir PharmaceuticalsN/A$4.25+4.7%N/AN/A$125.84MN/A0.001RANIRani Therapeutics3.1546 of 5 stars$2.31+0.9%$11.71+407.1%+20.9%$122.30M$2.72M-1.96110Gap Up Related Companies and Tools Related Companies PRPH Alternatives BTAI Alternatives TNXP Alternatives LPTX Alternatives MCRB Alternatives VXRT Alternatives ADAG Alternatives DERM Alternatives TELO Alternatives RANI Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LTRN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lantern Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lantern Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
